You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 4
  • PR088/#198  EZH2/EZH1 inhibitor tulmimetostat (CPI-0209): preliminary phase II results and first biomarker findings in patients with arid1a-mutant ovarian clear cell or endometrial carcinomas (OCCC/EC)

Article info

Article menu

Download PDFPDF

Featured Posters: Poster Rounds with the Professors
AS16. Screening/Early detection
PR088/#198  EZH2/EZH1 inhibitor tulmimetostat (CPI-0209): preliminary phase II results and first biomarker findings in patients with arid1a-mutant ovarian clear cell or endometrial carcinomas (OCCC/EC)
Free

Authors

Citation

Drescher C, Walter H, Pons-Tostivint E, et al
PR088/#198  EZH2/EZH1 inhibitor tulmimetostat (CPI-0209): preliminary phase II results and first biomarker findings in patients with arid1a-mutant ovarian clear cell or endometrial carcinomas (OCCC/EC)
International Journal of Gynecologic Cancer 2023;33:A80.

Publication history

  • First published November 7, 2023.
Online issue publication 
November 07, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.